跳至主要内容
临床试验/JPRN-jRCTs031180354
JPRN-jRCTs031180354已完成2 期

An interventional single arm study to confirm the safety of the Gastrointestinal hormone Ghrelin against chronic kidney disease patients.

Itoh Hiroshi0 个研究点目标入组 0 人开始时间: 2019年3月18日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方

研究概览

简要总结

We focused on a peptide hormone ghrelin. Due to the antioxidative effect of ghrelin, we thought that it might be effective against chronic kidney disease patients by improving the protein energy waisting syndrome and slowing down the progression of kidney dysfunction. There were many candidates but we could not make an agreement to participate in this study. We terminated this study because of the difficulty in obtaining ghrelin from the company.

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years old 至 not applicable(—)
性别
All

入选标准

  • Age 20 and up
  • Stage G4 and G5 Chronic Kidney Disease Patient of Keio University Hospital outpatient clinic who have not underwent dialysis
  • BMI lower than 25
  • Who have agreed to cooperate with this clinical study with an excellent understanding

排除标准

  • Who have severe liver dysfunction
  • Who have cancer
  • Who have severe infectious disease
  • Who have mental disorders
  • Who have allergy against wheat, eggs and milk
  • Women with a possibility of pregnancy
  • Who have been decided to be excluded by the primary doctor

研究者

发起方
Itoh Hiroshi

相似试验

To confirm the safety of the Gastrointestinal... | 临床试验